Immunic punts psoriasis, prostate cancer programs to narrow focus onto multiple sclerosis, celiac disease

Immunic can no longer keep all its balls in the air. Rather than keep advancing on three fronts, the firm has decided to deprioritize development in psoriasis and castration-resistant prostate cancer and throw its remaining resources at two other programs.